Identifying Chemicals with Potential Therapy of HIV Based on Protein-protein and Protein-chemical Interaction Network

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Jun 14

PMID 23762317

Citations 7

Authors

Bi-Qing Li

Bing Niu

Lei Chen

Ze-Jun Wei

Tao Huang

Min Jiang

Jing Lu

Ming-Yue Zheng

Xiang-Yin Kong

Yu-Dong Cai

Affiliations

Soon will be listed here.

Abstract

Acquired immune deficiency syndrome (AIDS) is a severe infectious disease that causes a large number of deaths every year. Traditional anti-AIDS drugs directly targeting the HIV-1 encoded enzymes including reverse transcriptase (RT), protease (PR) and integrase (IN) usually suffer from drug resistance after a period of treatment and serious side effects. In recent years, the emergence of numerous useful information of protein-protein interactions (PPI) in the HIV life cycle and related inhibitors makes PPI a new way for antiviral drug intervention. In this study, we identified 26 core human proteins involved in PPI between HIV-1 and host, that have great potential for HIV therapy. In addition, 280 chemicals that interact with three HIV drugs targeting human proteins can also interact with these 26 core proteins. All these indicate that our method as presented in this paper is quite promising. The method may become a useful tool, or at least plays a complementary role to the existing method, for identifying novel anti-HIV drugs.

Citing Articles

Identification of anticancer drug target genes using an outside competitive dynamics model on cancer signaling networks.

Tran T, Pham D Sci Rep. 2021; 11(1):14095.

PMID: 34238960 PMC: 8266823. DOI: 10.1038/s41598-021-93336-z.

CGINet: graph convolutional network-based model for identifying chemical-gene interaction in an integrated multi-relational graph.

Wang W, Yang X, Wu C, Yang C BMC Bioinformatics. 2020; 21(1):544.

PMID: 33243142 PMC: 7689985. DOI: 10.1186/s12859-020-03899-3.

Network-Based Analysis of OMICs Data to Understand the HIV-Host Interaction.

Ivanov S, Lagunin A, Filimonov D, Tarasova O Front Microbiol. 2020; 11:1314.

PMID: 32625189 PMC: 7311653. DOI: 10.3389/fmicb.2020.01314.

HIV-1, human interaction database: current status and new features.

Ako-Adjei D, Fu W, Wallin C, Katz K, Song G, Darji D Nucleic Acids Res. 2014; 43(Database issue):D566-70.

PMID: 25378338 PMC: 4383939. DOI: 10.1093/nar/gku1126.

A graphic method for identification of novel glioma related genes.

Gao Y, Shu Y, Yang L, He Y, Li L, Huang G Biomed Res Int. 2014; 2014:891945.

PMID: 25050377 PMC: 4094879. DOI: 10.1155/2014/891945.

References

Ju S, Goh A, Kwon D, Youn G, Kwon H, Bae Y . Extracellular HIV-1 Tat induces human beta-defensin-2 production via NF-kappaB/AP-1 dependent pathways in human B cells. Mol Cells. 2012; 33(4):335-41. PMC: 3887796. DOI: 10.1007/s10059-012-2287-0. View

Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y . Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem. 2006; 281(18):12688-98. DOI: 10.1074/jbc.M512688200. View

Greene W, Debyser Z, Ikeda Y, Freed E, Stephens E, Yonemoto W . Novel targets for HIV therapy. Antiviral Res. 2008; 80(3):251-65. DOI: 10.1016/j.antiviral.2008.08.003. View

Chen L, Lu J, Zhang J, Feng K, Zheng M, Cai Y . Predicting chemical toxicity effects based on chemical-chemical interactions. PLoS One. 2013; 8(2):e56517. PMC: 3574107. DOI: 10.1371/journal.pone.0056517. View

Bovolenta C, Lorini A, Mantelli B, Camorali L, Novelli F, Biswas P . A selective defect of IFN-gamma- but not of IFN-alpha-induced JAK/STAT pathway in a subset of U937 clones prevents the antiretroviral effect of IFN-gamma against HIV-1. J Immunol. 1999; 162(1):323-30. View

Rom S, Pacifici M, Passiatore G, Aprea S, Waligorska A, Del Valle L . HIV-1 Tat binds to SH3 domains: cellular and viral outcome of Tat/Grb2 interaction. Biochim Biophys Acta. 2011; 1813(10):1836-44. PMC: 3527102. DOI: 10.1016/j.bbamcr.2011.06.012. View

Keshava Prasad T, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S . Human Protein Reference Database--2009 update. Nucleic Acids Res. 2008; 37(Database issue):D767-72. PMC: 2686490. DOI: 10.1093/nar/gkn892. View

Ding J, Das K, Moereels H, Koymans L, Andries K, Janssen P . Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol. 1995; 2(5):407-15. DOI: 10.1038/nsb0595-407. View

Kino T, Pavlakis G . Partner molecules of accessory protein Vpr of the human immunodeficiency virus type 1. DNA Cell Biol. 2004; 23(4):193-205. DOI: 10.1089/104454904773819789. View

10.

Liu R, Paxton W, Choe S, Ceradini D, Martin S, Horuk R . Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996; 86(3):367-77. DOI: 10.1016/s0092-8674(00)80110-5. View

11.

Chan J, Greene W . Dynamic roles for NF-κB in HTLV-I and HIV-1 retroviral pathogenesis. Immunol Rev. 2012; 246(1):286-310. DOI: 10.1111/j.1600-065X.2012.01094.x. View

12.

Chan J, Greene W . NF-κB/Rel: agonist and antagonist roles in HIV-1 latency. Curr Opin HIV AIDS. 2011; 6(1):12-8. PMC: 3493179. DOI: 10.1097/COH.0b013e32834124fd. View

13.

Pinney J, Dickerson J, Fu W, Sanders-Beer B, Ptak R, Robertson D . HIV-host interactions: a map of viral perturbation of the host system. AIDS. 2009; 23(5):549-54. DOI: 10.1097/QAD.0b013e328325a495. View

14.

Joy M, Brock A, Ingber D, Huang S . High-betweenness proteins in the yeast protein interaction network. J Biomed Biotechnol. 2005; 2005(2):96-103. PMC: 1184047. DOI: 10.1155/JBB.2005.96. View

15.

Ren J, Esnouf R, Hopkins A, Ross C, Jones Y, Stammers D . The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure. 1995; 3(9):915-26. DOI: 10.1016/S0969-2126(01)00226-X. View

16.

Li B, Huang T, Liu L, Cai Y, Chou K . Identification of colorectal cancer related genes with mRMR and shortest path in protein-protein interaction network. PLoS One. 2012; 7(4):e33393. PMC: 3319543. DOI: 10.1371/journal.pone.0033393. View

17.

Danley D, Geoghegan K, Scheld K, Lee S, Merson J, Hawrylik S . Crystallizable HIV-1 protease derived from expression of the viral pol gene in Escherichia coli. Biochem Biophys Res Commun. 1989; 165(3):1043-50. DOI: 10.1016/0006-291x(89)92707-1. View

18.

Christ F, Voet A, Marchand A, Nicolet S, Desimmie B, Marchand D . Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol. 2010; 6(6):442-8. DOI: 10.1038/nchembio.370. View

19.

Ho D, Toyoshima T, Mo H, Kempf D, Norbeck D, Chen C . Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol. 1994; 68(3):2016-20. PMC: 236669. DOI: 10.1128/JVI.68.3.2016-2020.1994. View

20.

Girvan M, Newman M . Community structure in social and biological networks. Proc Natl Acad Sci U S A. 2002; 99(12):7821-6. PMC: 122977. DOI: 10.1073/pnas.122653799. View